Contact

La solution Sirius NeoSight vous intéresse et il vous reste des questions ?
Vous souhaitez investir dans le projet ou devenir partenaire ?
N’hésitez pas, contactez-nous. Nous nous ferons un plaisir de vous répondre.

La solution Sirius NeoSight vous intéresse et il vous reste des questions ?
Vous souhaitez investir dans le projet ou devenir partenaire ?
N’hésitez pas, contactez-nous. Nous nous ferons un plaisir de vous répondre.

Winner of the PRTK’s call for clinical projects

Thrilled to announce that the project, LIGHT-CTC is winner of the AAP PRT-K 2024 supported by the National Cancer Institute (INCa) and the DGOS.

This project will leverage the extensive scientific and medical expertise of the CRCL Centre de Recherche en Cancérologie de Lyon and the Centre Léon Bérard, internationally recognized for their excellence in cancer research and care.

Soft tissue sarcomas are rare cancers that unfortunately often affect adolescents and young adults. These diseases are highly heterogeneous and remain difficult to treat at the metastatic stage. By utilizing circulating tumor cells in the blood and an innovative isolation technology developed in partnership with the compagny Sirius Neosight, we aim to better tailor effective therapeutic strategies for each patient.
The impactive project will be supported by the innovative startup Sirius NeoSight (CEO: Agnès Bastid), housed within the CLB and pioneering cutting-edge CTC insulation and development techniques.

Sirius NeoSight is committed every day to providing cutting-edge solutions to cancer patients.

More information about the projects supported by INCa in the AAP PRTK-2024 https://lnkd.in/dGRYy_fQ

Aller au contenu principal